对于晚期NSCLC、腺癌或含腺癌成分的其他类型肺癌,应在诊断的同时常规进行EGFR基因突变和间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因检测。如有必要可进行c-ros原癌基因1酪氨酸激酶(c-ros oncogene 1 receptor tyrosine kinase, ROS1)基因及RET基因融合,K-RAS基因和BRAF基因V600E突变、人类表皮生长因子受体2(human epidermal growth factor receptor-2, HER2)基因扩增、MET基因高水平扩增及MET基因14号外显子跳跃缺失突变检测。. Here, RET is linked to non-small cell lung carcinoma.